Compare Hinge Health Inc. Class A Common Stock (HNGE) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs UiPath Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while UiPath Inc trades at $12.92 (market cap $6.91B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and UiPath Inc for 139 Days on average.
| HNGE | PATH | |
|---|---|---|
Market Cap | $8.48B | $6.91B |
Volume | 879,799 | 26,239,123 |
Sector | Health | Technology |
52-Week High | $105.14 | $19.29 |
52-Week Low | $31.17 | $9.38 |
Typical Hold Time | 0 Days | 139 Days |
Enterprise Value | $8.10B | $5.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
UiPath (PATH) trades at $13.06, down 1.95% on the day, with a bullish technical signal from moving averages but neutral oscillators. Revenue growth is robust, increasing from $1.3B in 2024 to $1.43B in 2025, with a projected net profit of $362M in 2026. Recent news highlights expanded AI partnerships and raised guidance, though the stock faces near-term volatility.
The outlook is cautiously optimistic, with a consensus price target of $15.13 offering potential upside. Key opportunities include strong enterprise demand and AI monetization, while risks involve competitive pressures and execution challenges in achieving profitability targets. Analyst sentiment is mixed, with a majority hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
